Dipeptidyl Peptidase-4 (DPP4) Inhibitors for Inhibiting Posterior Capsular Opacification
This invention utilizes dipeptidyl peptidase-4 (DPP4) inhibitors as a targeted treatment to prevent posterior capsular opacification (PCO), a common complication following cataract surgery. By inhibiting the molecular pathways that lead to lens clouding, this technology offers an effective, non-invasive alternative to traditional laser treatments for "secondary cataracts".
Description
The technology functions by delivering an effective amount of one or more DPP4 inhibitors—such as sitagliptin, saxagliptin, or vildagliptin—locally to the eye. After cataract surgery, elevated levels of transforming growth factor-beta (TGF-β) typically trigger a wound-healing response that causes residual lens epithelial cells (LECs) to undergo epithelial-mesenchymal transition (EMT). During this process, these cells migrate, proliferate, and differentiate into myofibroblasts, which secrete extracellular matrix components that lead to the wrinkling and opacification of the lens capsule. By specifically inhibiting DPP4 activity in these lens cells, the treatment attenuates the TGF-β-induced EMT pathway. This suppression reduces the expression of fibrotic markers (such as fibronectin and vimentin) and prevents the aberrant differentiation of cells that would otherwise cause "secondary cataracts". The inhibitors can be administered through various local delivery methods, including topical eye drops, drug-eluting contact lenses, or intraocular injections.Applications
- Post-Cataract Surgery Therapeutics: Topical eye drops or ointments for patients recovering from cataract extraction to prevent secondary opacification.- Drug-Eluting Intraocular Lenses: Integration of DPP4 inhibitors directly into artificial lenses for sustained, local drug release.
- Specialized Pediatric Eye Care: Targeted treatments for infants and children who have a significantly higher and earlier incidence of PCO.
- Combination Ophthalmic Therapies: Co-formulation with anti-inflammatory or anti-infective agents for comprehensive postoperative ocular care.
- Veterinary Ophthalmology: Prevention of PCO in non-human mammals undergoing cataract procedures.
Advantages
- Non-Invasive Prevention: Offers a pharmacological method to inhibit PCO, potentially eliminating the need for subsequent surgical or laser interventions.- Reduced Postoperative Risks: Provides an alternative to Nd:YAG laser capsulotomy, avoiding associated risks such as retinal detachment, macular edema, and increased intraocular pressure.
- High Efficacy: Demonstrates significant reduction in lens opacity and fibrotic marker expression (at least 20% and up to 99% inhibition) in experimental models.
- Versatile Administration: Formulations can be adapted into eye drops, ointments, or even drug-eluting artificial intraocular lenses (IOLs).
- Targeted Action: Specifically modulates the EMT process in residual lens epithelial cells to maintain long-term ocular clarity.